Efisio Puxeddu
Overview
Explore the profile of Efisio Puxeddu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2601
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moretti S, Mandarano M, Menicali E, Guzzetti M, Morelli S, Talpacci E, et al.
J Clin Endocrinol Metab
. 2024 Sep;
PMID: 39328078
Context: Anaplastic thyroid carcinomas (ATCs) and poorly differentiated thyroid carcinomas (PDTCs) exhibit distinct immune-related gene expression profiles. Most ATCs are characterized by active immune interactions (hot or altered immunosuppressed immunophenotypes),...
2.
Grani G, DElia S, Puxeddu E, Morelli S, Arvat E, Nervo A, et al.
J Clin Endocrinol Metab
. 2024 Aug;
PMID: 39150986
Context: The utility of thyroglobulin (Tg) in the follow-up of differentiated thyroid cancer (DTC) patients has been well-documented. Although third-generation immunoassays have improved accuracy, limitations persist (interfering anti-Tg antibodies and...
3.
De Angelis S, Medda E, Rotondi D, Masocco M, Minardi V, Contoli B, et al.
J Clin Endocrinol Metab
. 2023 Oct;
109(2):e495-e507.
PMID: 37820735
Context: In 2005, a nationwide program of iodine prophylaxis on a voluntary basis was implemented in Italy by law. However, recent data on iodine status are lacking. Objective: The aim...
4.
De Leo S, DElia S, Grani G, Dondi F, Bertagna F, Puxeddu E, et al.
Thyroid
. 2023 Sep;
33(11):1318-1326.
PMID: 37725571
There is some controversy on the potential relationship between autoimmune processes and clinicopathologic features as well as prognosis of differentiated thyroid cancer (DTC), and the evidence is limited by its...
5.
Bianconi E, Riccio A, Ruta L, Bigiotti C, Carotti A, Moretti S, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982608
PD-1/PD-L1 protein complex is attracting a great deal of interest as a drug target for the design of immune therapies able to block its assembly. Although some biologic drugs have...
6.
Grani G, Gentili M, Siciliano F, Albano D, Zilioli V, Morelli S, et al.
J Clin Endocrinol Metab
. 2023 Feb;
108(8):1921-1928.
PMID: 36795619
Context: The risk stratification of patients with differentiated thyroid cancer (DTC) is crucial in clinical decision making. The most widely accepted method to assess risk of recurrent/persistent disease is described...
7.
Valerio L, Cantara S, Puxeddu E, Castagna M
Front Endocrinol (Lausanne)
. 2022 Apr;
13:891903.
PMID: 35464069
No abstract available.
8.
Mandarano M, Andolfi M, Colella R, Monacelli M, Polistena A, Moretti S, et al.
J Clin Med
. 2021 Oct;
10(19).
PMID: 34640369
Primary thyroid tumours show different levels of aggressiveness, from indolent to rapidly growing infiltrating malignancies. The most effective therapeutic option is surgery when radical resection is feasible. Biomarkers of aggressiveness...
9.
Forleo R, Grani G, Alfo M, Zilioli V, Giubbini R, Zatelli M, et al.
Thyroid
. 2021 Sep;
31(12):1814-1821.
PMID: 34541894
The role of minimal extrathyroidal extension (mETE) as a risk factor for persistent papillary thyroid carcinoma (PTC) is still debated. The aims of this study were to assess the clinical...
10.
Tao Y, Wang F, Shen X, Zhu G, Liu R, Viola D, et al.
J Clin Endocrinol Metab
. 2021 Jul;
106(11):3228-3238.
PMID: 34273152
Context: How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined. Objective: To study whether BRAF V600E affected LNM-associated mortality in...